Volume 3, Issue 2 (April 2024)                   Health Science Monitor 2024, 3(2): 120-128 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ezati E, Barati M, Darabi F, Ezzati Rastegar K, Safarzadeh B, Morsali A. Evaluation of the effect of vaccination and its consequences in patients with COVID-19 in western Iran. Health Science Monitor 2024; 3 (2) :120-128
URL: http://hsm.umsu.ac.ir/article-1-152-en.html
Assistant, Dept. of Public Health, Asadabad School of Medical Sciences Asadabad, Iran
Abstract:   (959 Views)
Background & Aims: The confirmed cases of the new coronavirus disease (COVID-19) have increased not only in China but also in Iran and around the world. COVID-19 vaccination not only protects the individual but also safeguards those in the community who are unable to be vaccinated. Due to this concern, the present study was conducted to determine the relationship between vaccination and its consequences in patients with COVID-19.
Materials & Methods: This descriptive study was conducted in Asadabad city, in western Iran. The data for this project were collected from the database and records of patients with COVID-19 in Asadabad Health Department. In fact, the sample size included all patients with a positive PCR diagnosis in the year 2022. Nine hundred fifty-one patients were included in the study. The tool used was a checklist based on patient records. SPSS software was used to analyze the data, and a significance level of less than 0.05 was considered.
Results: The mean age of patients with a positive PCR test was 20.8 ± 42.9 years. Of these, 68.5% were vaccinated, and 31.5% were not vaccinated. Among the 951 patients, 30 patients with a positive PCR died, 19 of whom were not vaccinated. There was a significant relationship between the outcome of the disease (death or discharge) and the number of vaccine doses (p value = 0.001).
Conclusion: Due to the effectiveness of COVID vaccination in reducing hospitalization and mortality, it is recommended to design educational interventions to encourage people to increase vaccination coverage.
Full-Text [PDF 313 kb]   (403 Downloads)    
Type of Study: Research | Subject: Health promotion and disease prevention
Received: 2023/11/23 | Accepted: 2024/04/15 | Published: 2024/04/9

References
1. Pouya MJ, Yaghoubi S, Darabi F, Mousavi Z, Falahi J. Environmental Surface Circulation of SARS-CoV-2 RNA in Asadabad Hospital Wards. Clinical Laboratory. 2022 Feb 1;68(2). [DOI] [PMID]
2. Suwantika AA, Zakiyah N, Diantini A, Abdulah R, Postma MJ. The role of administrative and secondary data in estimating the costs and effects of school and workplace closures due to the covid-19 pandemic. Data. 2020;5(4):98. [DOI]
3. Moradi A, Mirzaei M, Ameri P, Zangeneh M, Moradi A, Darabi F. Spatial Analysis of Covid-19 Disease in Hamadan Province. Payesh 2024; 23 (2) :271-287. https://doi.org/ 10.61186/payesh.23.2.271 [DOI]
4. Candelli M, Pignataro G, Torelli E, Gullì A, Nista EC, Petrucci M, et al. Effect of influenza vaccine on COVID-19 mortality: A retrospective study. Internal and Emergency Medicine. 2021;16(7):1849-55. [DOI] [PMID] [PMCID]
5. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. The Lancet Infectious Diseases. 2020;20(7):773. [DOI] [PMID]
6. Coronavirus disease. New cases and deaths. Available at: https://www.worldometers.info/coronavirus/country/iran/. [URL]
7. Takian A, Raoofi A, Kazempour-Ardebili S. COVID-19 battle during the toughest sanctions against Iran. The Lancet. 2020;395(10229):1035. [DOI] [PMID]
8. Kumari A, Ranjan P, Chopra S, Kaur D, Kaur T, Upadhyay AD, et al. Knowledge, barriers and facilitators regarding COVID-19 vaccine and vaccination programme among the general population: a cross-sectional survey from one thousand two hundred and forty-nine participants. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15(3):987-92. [DOI] [PMID] [PMCID]
9. Centers for Disease Control and Prevention. Science Brief: COVID-19 Vaccines and Vaccination. Available at: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/index.html. [URL]
10. Díaz J, Antonio-López-Bueno J, Culqui D, Asensio C, Sánchez-Martínez G, Linares C. Does exposure to noise pollution influence the incidence and severity of COVID-19? Environmental Research. 2021;195:110766. [DOI] [PMID] [PMCID]
11. Noor FM, Islam M. Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis. Journal of Community Health. 2020;45(6):1270-82. [DOI] [PMID] [PMCID]
12. Gupta S, Cantor J, Simon KI, Bento AI, Wing C, Whaley CM. Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States: Study examines role of COVID-19 vaccines and deaths averted in the United States. Health Affairs. 2021. [DOI] [PMID] [PMCID]
13. Taghinezhad-S S, Mohseni AH, Bermúdez-Humarán LG, Casolaro V, Cortes-Perez NG, Keyvani H, et al. Probiotic-based vaccines may provide effective protection against COVID-19 acute respiratory disease. Vaccines. 2021;9(5):466. [DOI] [PMID] [PMCID]
14. World Health Organization. Coronavirus disease (COVID-19): Vaccines. Available at: https://www.who.int/news-room/q-and-a/detail/covid-19-vaccines. [URL]
15. Roghani A. The influence of Covid-19 vaccine on daily cases, hospitalization, and death rate in Tennessee: a case study in the United States. medRxiv. 2021. [DOI]
16. Li H, Wang S, Zhong F, Bao W, Li Y, Liu L, et al. Age-dependent risks of incidence and mortality of COVID-19 in Hubei Province and other parts of China. Frontiers in Medicine. 2020;7:190. [DOI] [PMID] [PMCID]
17. Yang M-J, Rooks BJ, Le T-TT, Santiago IO, Diamond J, Dorsey NL, et al. Influenza vaccination and hospitalizations among COVID-19 infected adults. Journal of the American Board of Family Medicine. 2021;34(Supplement):S179-S82. [DOI] [PMID]
18. Algaissi AA, Alharbi NK, Hassanain M, Hashem AM. Preparedness and response to COVID-19 in Saudi Arabia: Building on MERS experience. Journal of Infection and Public Health. 2020;13:834-8. [DOI] [PMID] [PMCID]
19. Dal-Ré R, Caplan AL, Gluud C, Porcher R. Ethical and scientific considerations regarding the early approval and deployment of a COVID-19 vaccine. Annals of Internal Medicine. 2021;174:258-60. [DOI] [PMID] [PMCID]
20. Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S, et al. Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia. Vaccines. 2021;9:674. [DOI] [PMID] [PMCID]
21. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, et al. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. Clinical Infectious Diseases. 2021;73(12):2257-64. [DOI] [PMID] [PMCID]
22. Ghiasi N, Valizadeh R, Arabsorkhi M, Hoseyni TS, Esfandiari K, Sadighpour T, et al. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. Immunopathologia Persa. 2021;7(2):e31-e. [DOI]
23. Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Network Open. 2021;4(12):e2140364. [DOI] [PMID] [PMCID]
24. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020;383:2603-15. [DOI] [PMID] [PMCID]
25. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397:99-111. [DOI] [PMID]
26. Taherian Z, Rezaei M, Haddadpour A, Amini Z. The Effect of COVID-19 Vaccination on Reducing the Risk of Infection, Hospitalization, and Death in Isfahan Province, Iran. Iranian Journal of Public Health. 2022;51(1):188. [DOI]
27. Wise J. Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval. British Medical Journal. 2021. [DOI] [PMID]
28. Bernal JL, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. MedRxiv. 2021. [DOI]
29. Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Nesher L, Stein M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clinical Microbiology and Infection. 2021;27(11):1652-7. [DOI] [PMID] [PMCID]
30. Wong LP, Wong PF, AbuBakar S. Vaccine hesitancy and the resurgence of vaccine preventable diseases: the way forward for Malaysia, a Southeast Asian country. Human Vaccines & Immunotherapeutics. 2020;16(7):1511-20. [DOI] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 All Rights Reserved | Health Science Monitor

Designed & Developed by : Yektaweb